Drug Trial Radar · NCT05794230
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,528
Actual
Start
Mar 27, 2023
Primary completion
Nov 15, 2025
Study completion Nov 15, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This open label randomized study will be conducted to evaluate and/or describe the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered in infants and toddlers. It will be conducted in India and the RSA in 2 cohorts: * Cohort I: Infants and toddlers 6 months to 16 months of age (Cohort I) * Cohort II: Infants and toddlers 6 weeks to 15 months of age (Cohort II) In Cohort I, eligible participants will be randomized in a 1:1 ratio to receive 2 intramuscular (IM) injections (1+1 vaccination schedule) of either MenACYW conjugate vaccine (Groups 1 and 3) or Menactra vaccine (Groups 2 and 4), co-administered with routine pediatric vaccines. In Cohort II, eligible participants will be randomized in a 2:1 ratio to receive either 3 IM injections (2+1 vaccination schedule) of MenACYW conjugate vaccine co-administered with routine pediatric vaccines (Groups 5 and 7) or routine pediatric vaccines only (Groups 6 and 8). The primary objectives of this study are: * To demonstrate the non-inferiority of immunogenicity of 2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in terms of serum bactericidal assay using human complement (hSBA) seroprotection (titers ≥ 1:8) in India and the Republic of South Africa (RSA) * To demonstrate the vaccine immune sufficiency of 3 doses of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in terms of hSBA seroprotection (titers ≥ 1:8) in India and the RSA The secondary objectives of this study are: * To describe the antibody titers to the meningococcal serogroups A, C, Y, and W: * before and 30 days post primary series of MenACYW conjugate vaccine and before and 30 days post booster dose of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with other age-recommended vaccines. * before and after 30 days post each dose of MenACYW conjugate vaccine or Menactra vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the antibody responses against the antigens of the other age-recommended vaccines when administered concomitantly with MenACYW conjugate vaccine: * in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA. * in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA. * To describe the safety profile of MenACYW conjugate vaccine and that of licensed Menactra vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the safety profile of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the safety profile of age-recommended vaccines: * in infants 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with MenACYW conjugate vaccine. * in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with MenACYW conjugate vaccine. The duration of each participant's active participation in the study will be approximately 10 to 11 months for Cohort I and 13,5 to 14,5 months for Cohort II.
Conditions
- Meningococcal Immunisation
- Healthy Volunteers
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological
Liquid solution - intramuscular
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological
Liquid solution - intramuscular
Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)Biological
Oral suspension - oral
Pneumoccocal VaccineBiological
Suspension for injection - intramuscular
Measles, Mumps, and Rubella Vaccine live (MMR)Biological
Lyophilized powder for injection - subcutaneous
DTwP-HepB-Hib-IPV vaccineBiological
Suspension - intramuscular
DTaP-IPV-Hib-HepB vaccineBiological
Liquid solution - intramuscular
Hepatitis A vaccineBiological
Lyophilized powder for injection - subcutaneous
Rotavirus vaccineBiological
Oral solution - oral
Typhoid conjugate vaccine (TCV)Biological
Suspension for injection - intramuscular
Measles vaccineBiological
Freeze-dried powder for reconstitution and injection - subcutaneous
Varicella vaccine liveBiological
Sterile powder and diluent for injection - subcutaneous
Varicella vaccine liveBiological
Lyophilized powder for injection - subcutaneous
Measles, Mumps, and Rubella Vaccine live (MMR)Biological
Lyophilized powder for injection - subcutaneous
Hepatitis A vaccineBiological
Suspension for injection - intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with anti-meningococcal serogroups A, C, Y, W antibody titers above predefined thresholds after 2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine in infants and toddlers 6 months to 16 months of ageTime frame: 30 days after the second vaccination
- Percentage of participants with anti-meningococcal serogroups A, C, Y, W Ab titers above predefined thresholds after 3 doses of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of ageTime frame: 30 days after the booster vaccination
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number : 3560006
Chennai, India
Investigational Site Number : 3560007
Hyderabad, India
Investigational Site Number : 3560016
Kanpur, India
Investigational Site Number : 3560009
Kolkata, India
Investigational Site Number : 3560011
Manipal, India
Investigational Site Number : 3560013
Mysore, India
Investigational Site Number : 3560004
Mysore, India
Investigational Site Number : 3560003
New Delhi, India
Investigational Site Number : 3560002
Pune, India
Investigational Site Number : 3560001
Pune, India
Investigational Site Number : 7100002
Cape Town, South Africa
Investigational Site Number : 7100003
Cape Town, South Africa
Investigational Site Number : 7100006
George, South Africa
Investigational Site Number : 7100005
Johannesburg, South Africa
Investigational Site Number : 7100001
Middelburg, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.